Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer

World Journal of Gastroenterology

Volumn 15, Issue 14, 2009, Pages 1719-1729

  Peng, Tie Li ^a   Chen, Jie ^a   Mao, Wei ^a   Liu, Xin ^a   Tao, Yu ^a   Chen, Lian Zhou ^a   Chen, Min Hu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Aryl hydrocarbon receptor; Cell cycle; Cell proliferation; Gastric cancer

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR;

APOPTOSIS; ARTICLE; ATROPHIC GASTRITIS; CANCER CELL CULTURE; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL HYPERPLASIA; CELL PROLIFERATION; CELL VIABILITY; CHRONIC GASTRITIS; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; PRECANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING; ADULT; AGED; CELL CYCLE; CYTOLOGY; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; POLLUTANT; STOMACH; STOMACH TUMOR; TUMOR CELL LINE;

ADULT; AGED; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PRECANCEROUS CONDITIONS; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS; TETRACHLORODIBENZODIOXIN;

EID: 65649114010     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1719     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 58-60
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740
4. Chen J, Röcken C, Malfertheiner P, Ebert MP. Recent advances in molecular diagnosis and therapy of gastric cancer. Dig Dis 2004; 22: 380-385
5. Sinha R, Rothman N. Role of well-done, grilled red meat, heterocyclic amines (HCAs) in the etiology of human cancer. Cancer Lett 1999; 143: 189-194
6. Athar M, Khan WA, Mukhtar H. Effect of dietary tannic acid on epidermal, lung, and forestomach polycyclic aromatic hydrocarbon metabolism and tumorigenicity in Sencar mice. Cancer Res 1989; 49: 5784-5788
7. Bock KW. Aryl hydrocarbon or dioxin receptor: biologic and toxic responses. Rev Physiol Biochem Pharmacol 1994; 125: 1-42
8. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003; 43: 309-334
9. Lin P, Chang H, Tsai WT, Wu MH, Liao YS, Chen JT, Su JM. Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol Pathol 2003; 31: 22-30
10. Henry EC, Bemis JC, Henry O, Kende AS, Gasiewicz TA. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch Biochem Biophys 2006; 450: 67-77
11. Vrzal R, Ulrichová J, Dvorák Z. Aromatic hydrocarbon receptor status in the metabolism of xenobiotics under normal and pathophysiological conditions. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004; 148: 3-10
12. Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 2006; 387: 1175-1187
13. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 2005; 96: 1174-1184
14. Kim JH, Kim H, Lee KY, Kang JW, Lee KH, Park SY, Yoon HI, Jheon SH, Sung SW, Hong YC. Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. Lung Cancer 2007; 56: 9-15
15. Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, Dai Q, Holtzman J, Gao YT, Zheng W. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics 2006; 16: 237-243
16. Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Büchler MW, Friess H. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 2002; 21: 6059-6070
17. Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L, Schwarz M. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 2004; 64: 4707-4710
18. Bradshaw TD, Trapani V, Vasselin DA, Westwell AD. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? Curr Pharm Des 2002; 8: 2475-2490
19. Andersson P, McGuire J, Rubio C, Gradin K, Whitelaw ML, Pettersson S, Hanberg A, Poellinger L. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci USA 2002; 99: 9990-9995
20. Andersson P, Rubio C, Poellinger L, Hanberg A. Gastric hamartomatous tumours in a transgenic mouse model expressing an activated dioxin/Ah receptor. Anticancer Res 2005; 25: 903-911
21. Kuznetsov NV, Andersson P, Gradin K, Stein P, Dieckmann A, Pettersson S, Hanberg A, Poellinger L. The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis. Oncogene 2005; 24: 3216-3222
22. Chen J, Röcken C, Klein-Hitpass L, Götze T, Leodolter A, Malfertheiner P, Ebert MP. Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2′-deoxycytidine. Clin Exp Metastasis 2004; 21: 389-397
23. Ma JX, Zhang KL, Liu X, Ma YL, Pei LN, Zhu YF, Zhou L, Chen XY, Kong QY, Li H, Liu J. Concurrent expression of aryl hydrocarbon receptor and CYP1A1 but not CYP1A1 MspI polymorphism is correlated with gastric cancers raised in Dalian, China. Cancer Lett 2006; 240: 253-260
24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181
25. Hamilton SR, Aaltonen LA. WHO classification of tumours. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press, 2000: 93-102
26. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49
27. Chen J, Röcken C, Hoffmann J, Krüger S, Lendeckel U, Rocco A, Pastorekova S, Malfertheiner P, Ebert MP. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005; 54: 920-927
28. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 1998; 58: 5707-5712
29. Revel A, Raanani H, Younglai E, Xu J, Rogers I, Han R, Savouret JF, Casper RF. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 2003; 23: 255-261
30. Trombino AF, Near RI, Matulka RA, Yang S, Hafer LJ, Toselli PA, Kim DW, Rogers AE, Sonenshein GE, Sherr DH. Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res Treat 2000; 63: 117-131
31. Kress S, Greenlee WF. Cell-specific regulation of human CYP1A1 and CYP1B1 genes. Cancer Res 1997; 57: 1264-1269
32. Christou M, Savas U, Schroeder S, Shen X, Thompson T, Gould MN, Jefcoate CR. Cytochromes CYP1A1 and CYP1B1 in the rat mammary gland: cell-specific expression and regulation by polycyclic aromatic hydrocarbons and hormones. Mol Cell Endocrinol 1995; 115: 41-50
33. Zhang KL, Ma JX, Chen XY, Sun Y, Kong QY, Liu J, Li H. Frequent CYP1A1 expression in gastric cancers and their related lesions. Oncol Rep 2004; 12: 1335-1340
34. Giannone JV, Li W, Probst M, Okey AB. Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol 1998; 55: 489-497
35. Pollenz RS. The aryl-hydrocarbon receptor, but not the aryl-hydrocarbon receptor nuclear translocator protein, is rapidly depleted in hepatic and nonhepatic culture cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Pharmacol 1996; 49: 391-398
36. Li W, Harper PA, Tang BK, Okey AB. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem Pharmacol 1998; 56: 599-612
37. Pollenz RS. The mechanism of AH receptor protein downregulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem Biol Interact 2002; 141: 41-61
38. Roblin S, Okey AB, Harper PA. AH receptor antagonist inhibits constitutive CYP1A1 and CYP1B1 expression in rat BP8 cells. Biochem Biophys Res Commun 2004; 317: 142-148
39. Lee JE, Safe S. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol 2001; 62: 1113-1124
40. McDougal A, Wilson C, Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 1997; 120: 53-63